Autoimmune hepatitis: An approach to disease understanding and management

British Medical Bulletin

Volumn 114, Issue 1, 2015, Pages 181-191

  Corrigan, Margaret ^a   Hirschfield, Gideon M ^a   Oo, Ye H ^a   Adams, David H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Autoimmune liver disease; Azathioprine; Immune mediated liver disease; Prednisolone

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; STEROID; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; AUTOIMMUNE HEPATITIS; BILIARY TRACT DISEASE; DISEASE ACTIVITY; DISEASE PREDISPOSITION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT FAILURE; TREATMENT RESPONSE; HEPATITIS, AUTOIMMUNE; IMMUNOLOGY; PATIENT SELECTION; RECURRENT DISEASE;

AZATHIOPRINE; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PATIENT SELECTION; RECURRENCE; REMISSION INDUCTION;

EID: 84942055384     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldv021     Document Type: Article

References (32)

1. Bonito AJ, Aloman C, Fiel MI, et al. Medullary thymic epithelial cell depletion leads to autoimmune hepatitis. J Clin Invest 2013;123:3510-24.
2. Gleeson D, Heneghan MA, British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011;60:1611-2.
3. Floreani A, Liberal R, Vergani D, et al. Autoimmune hepatitis: contrasts and comparisons in children and adults-a comprehensive review. J Autoimmun 2013;46:7-16.
4. Al-Chalabi T, Underhill JA, Portman BC, et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008;48:140-7.
5. Teufel A, Weinmann A, Kahaly GJ, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol 2010;44:208-13.
6. Lohse AW, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol 2011;55:171-82.
7. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31: 929-38.
8. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-76.
9. Kirk AP, Jain S, Pocock S, et al. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in Hepatits B surface antigen negative chronic active hepatitis. Gut 1980;21:78-83.
10. Murray-Lyon I, Stern RB,Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1:735-7.
11. Stellon A, Keating J, Johnson P, et al. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988;8:781-3.
12. Hoeroldt B, McFarlane E, Dube A, et al. Long term outcomes of patients with autoimmune hepatitis managed at a non transplant centre. Gastroenterology 2011;140: 1980-9.
13. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193-213.
14. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010;139:1198-206.
15. Dhaliwal HK, Anderson R, Thornhill EL, et al. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis. Hepatology 2012;56:1401-8.
16. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as a second therapy in autoimmune hepatitis? Am J Gastrenterol 2008;103:3063-70.
17. Hartl J, Ehlken H, Weiler-Normann C, et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol 2015;62:642-6.
18. Czaja AJ. Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis. Aliment Pharmacol Ther 2014;39:1043-58.
19. Weiler-Normann C, Lohse AW. Autoimmune hepatitis: a life-long disease. J Hepatol 2013;58:5-7.
20. Aqel BA, Machico V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38:805-9.
21. Sherman KE, Narkewicz M, Pinto PC. Ciclosporin in the management of corticosteroid resistant type 1 autoimmune chronic active hepatitis. J Hepatol 1994;21:1040-7.
22. Burak KW, Swain MG, Santodomingo-Garzon T, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 2013;27:273-80.
23. Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult to treat autoimmune hepatitis. J Hepatol 2013;58:529-34.
24. Chazouillieres O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296-301.
25. Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children: what is different from adult AIH. Semi Liv Dis 2009;29:297-306.
26. De Boer YS, van Gernen N, Zwiers A, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 2014;147: 443-52.
27. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
28. Grant CR, Liberal R, Holder BS, et al. Dysfunctional CD39 (POS) regulatory T cells and aberrant control of T helper type 17 cells in autoimmune hepatitis. Hepatology 2014;59:1007-15.
29. Longhi MS, Liberal R, Holder B, et al. Inhibition of interleukin 17 promotes differentiation of CD25 cells into stable T regulatory cells in patients with autoimmune hepatitis. Gastroenterology 2012;142:1526-35.
30. Longhi MS, Hussain MJ, KwokWW, et al. Autoantigenspecific regulatory T cells, a potential tool for immune tolerance reconstitution in type 2 autoimmune hepatitis. Hepatology 2011;53:536-47.
31. Oo YH,Weston CJ, Lalor PJ, et al. Distinct roles for CCR4 and Cxcr3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol 2010; 184:2886-98.
32. Oo YH, Adams DH. Regulatory T cells and autoimmune hepatitis: what happens in the liver stays in the liver. J Hepatol 2014;61:973-5.